logo
ProjectOngoing

Decoding consequences of complex chromosomal aberrations by multi-modal single-cell deconstruction to overcome treatment-resistance cancer

One of 10,000+ projects Taiyo tracks in Germany.

Source: EU Funding & Tenders Portal

How does a cell with unstable, complex genomic rearrangements stay alive, and even give rise to aggressive, highly resistant malignancies? This question remains an ultimate research challenge for cancers with highly aberrant genomes, such as acute myeloid leukemia with complex karyotype (CK-AML). Its etiology, time-resolved clonal dynamics, molecular heterogeneity, and treatment resistance mechani

Status
Under Construction
Location
Germany
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Decoding consequences of complex chromosomal aberrations by multi-modal single-cell deconstruction to overcome treatment-resistance cancer

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Decoding consequences of complex chromosomal aberrations by multi-modal single-cell deconstruction to overcome treatment-resistance cancer” is an infrastructure initiative, located in Germany. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

How does a cell with unstable, complex genomic rearrangements stay alive, and even give rise to aggressive, highly resistant malignancies? This question remains an ultimate research challenge for cancers with highly aberrant genomes, such as acute myeloid leukemia with complex karyotype (CK-AML). Its etiology, time-resolved clonal dynamics, molecular heterogeneity, and treatment resistance mechanisms are still largely elusive. In particular, the genetic and non-genetic dynamics that drive cancer progression under treatment are elusive to current technologies and escape single-cell resolution. SHATTER-AML will tackle the genomic enigma of CK-AML by analyzing longitudinally obtained triplicate (diagnosis, treated, relapse) samples to examine intra-patient genetic and non-genetic heterogeneity using scNOVA-CITE, a newly developed multi-modal single-cell omics approach. This approach combines (i) structural variation discovery with nucleosome occupancy and cis-regulatory element accessibility profiling (scNOVA) with (ii) cellular indexing of transcriptomes and epitome sequencing (CITE-seq). We will uncover multi-level disease dynamics at single-cell and subclonal levels along the disease course, providing a blueprint for studies of other structurally instable cancers. Identified molecular insights into the networks mediating therapy resistance, leukemic stem cell activity and immune escape will be further explored functionally in patient-derived in vivo models. Pharmacological interference and CRISPRi are used to engineer deregulated signaling pathways for precision oncology, and CRISPRa screens are applied to sensitize CK-AML stem cells to natural killer cell-mediated elimination. • SHATTER-AML will fundamentally transform our understanding of the impact of clonal evolutionary dynamics of malignancies triggered by aberrant genomes and aims to develop novel preclinical strategies to combat CK-AML resistance via immunological and precision oncology approaches.

Location

Country

Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project